Antimicrobial and cleansing composition consisting of a polymeric biguanide and EDTA
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11266683-B2
Publication Date
2022-03-08
Expiration Date
Abstract
The invention relates to a antimicrobial and cleansing composition consisting of a. a polymeric biguanide, and b. a metal ion chelating agent, and g. a solvent, wherein the ratio of a:b is between 0.75:2.25 and 1.25:2.25, or about 1:2, and optionally one or more of the following ingredients; c. a quaternary ammonium salt, d. at least one surfactant, e. a humectant and f. a gelling agent. The invention further relates to said composition for use in a treatment, prevention or reduction of a disease, disorder or condition related to microbials, or treatment, prevention or reduction of infection, or inflammation, or infected wounds, or inflamed wounds, or treatment, prevention or reduction of biofilms, or removal of necrotic tissue. A liquid flow system may be used for administration of the composition.
Core Innovation
The invention describes an antimicrobial and cleansing composition that is non-alcoholic and liquid, comprising polyhexamethylene biguanide and EDTA in a defined component relationship with a solvent. The ratio of polyhexamethylene biguanide to EDTA is between 0.75:2.25 and 1:2.
The composition optionally includes quaternary ammonium salts, surfactants, humectant, and a gelling agent. It is formulated to be effective for antimicrobial and cleansing purposes while emphasizing low or negligible cellular toxicity and synergy at low doses.
The document also describes applications in antimicrobial treatment contexts, including biofilm disruption and necrotic tissue removal. It further describes a negative pressure fluid flow delivery system for applying the composition to infected soft tissue or bone, including use with wound exudate collection and a holding time of 5–60 minutes.
Claims Coverage
The document includes one independent claim. It covers an antimicrobial and cleansing liquid composition defined by polyhexamethylene biguanide, EDTA, and a solvent, with a constrained polyhexamethylene biguanide:EDTA ratio, and dependent claims refine ingredient classes and delivery or treatment framing.
Polyhexamethylene biguanide-to-EDTA ratio-defined antimicrobial and cleansing composition
An antimicrobial and cleansing composition comprising polyhexamethylene biguanide and EDTA with a solvent, wherein the ratio of polyhexamethylene biguanide to EDTA is between 0.75:2.25 and 1:2.
Specified ingredient refinements for the antimicrobial composition
The composition is further defined to include quaternary ammonium salts, surfactants that are non-ionic or amphoteric and/or satisfy an HLB-based constraint, a humectant, and a gelling agent, as refined by the dependent claim limitations.
Therapeutic administration for selected conditions
A method of treating or reducing a disease, disorder, or condition by administering a therapeutically effective amount of the composition to a subject.
Negative-pressure delivery system with wound holding time
A liquid flow system for delivering a composition from a reservoir to infected soft tissue or bone using a negative pressure source, including wound exudate collection, a negative pressure wound dressing, and fluid drawn away after a holding time of 5 to 60 minutes.
Overall, claim coverage centers on an antimicrobial and cleansing composition defined by polyhexamethylene biguanide and EDTA at a constrained ratio, with dependent coverage refining optional formulation components and adding treatment framing and a negative-pressure delivery system with a specified holding time.
Stated Advantages
Low or negligible cellular toxicity.
Synergy at low doses.
Broad antimicrobial activity, including MRSA and Pseudomonas.
Disruption of biofilm.
Removal of necrotic tissue.
Similar wound-healing efficacy compared with Medical honey (Medihoney) in the described animal study.
Documented Applications
Long-term wound treatment, including contexts involving biofilm disruption and necrotic tissue removal.
Treatment of infected soft tissue or bone using a negative pressure wound therapy delivery system with a holding time of 5–60 minutes.
In an animal study, daily topical application to wounds using the disclosed composition versus Medihoney, evaluated by wound contraction and histopathology scoring.
Interested in licensing this patent?